Physician profile
Emma Heller
NPI 1285304956
$4,317.79
in general payments reported to CMS, 2019-2025
14 companies · $594 in 2025
The $594 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $547 · 2022: $1,433 · 2023: $1,388 · 2024: $356 · 2025: $594.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,338.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,869.35 | 2021-2025 | |
| Gilead Sciences, INC. | $331.90 | 2022-2024 | Livdelzi, Epclusa |
| Regeneron Healthcare Solutions, INC. | $312.31 | 2022-2025 | Dupixent |
| Intra-Sana Laboratories | $292.17 | 2022-2023 | Reltone 200 Mg, Reltone 400 Mg, Glycate |
| Intercept Pharmaceuticals, INC. | $278.29 | 2021-2023 | Ocaliva |
| E.R. Squibb & Sons, L.L.C. | $261.24 | 2022-2023 | Zeposia |
| Genzyme Corporation | $172.76 | 2025 | |
| Janssen Scientific Affairs, LLC | $125.22 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $125.00 | 2023 | Gattex |
| Novo Nordisk INC | $124.74 | 2025 | Wegovy |
| Aimmune Therapeutics, INC. | $124.74 | 2025 | Zenpep |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $122.51 | 2021-2023 | Xifaxan |
| Evoke Pharma, INC. | $109.85 | 2021 | |
| Mallinckrodt Hospital Products INC. | $67.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emma Heller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.